Preparation method of mussel mucin based on genetic engineering modification
Through genetic engineering and dopa group modification, the adhesion ability and yield of mussel mucins are optimized, and the problems of poor adhesion effect and low yield in the prior art are solved, and efficient mussel mucin preparation is achieved. Suitable for the fields of medicine and bioengineering.
Patent Information
- Application Number
- CN202411185594.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-27
- Publication Date
- 2024-11-12
AI Technical Summary
Existing mussel mucins have poor adhesion on the surface of some materials, low yield, complex purification process and low efficiency, making it difficult to maintain biological activity.
Through genetic engineering, the dopa group modification enzyme was introduced, and the culture conditions were optimized. Combined with technologies such as centrifugation, ultrafiltration, affinity chromatography, ion exchange chromatography and gel filtration chromatography were used to perform chemical modification to improve adhesion ability and yield. , and concentrated and lyophilized under low temperature vacuum conditions.
It significantly improves the adhesion ability and yield of mussel mucin, enhances its firmness and durability on the surface of the material, and improves purity and biological activity, and is suitable for the fields of medicine and bioengineering.
Smart Images

Figure CN118930630A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of biomedical materials, and in particular to a method for preparing mussel mucin based on genetic engineering modification. Background Art
[0002] Mussel mucin is a low molecular weight, low isomerism, water-soluble protein, whose main components are collagen and mucopolysaccharide. Mussel mucin has high gelling properties and viscosity in aqueous solution and can form colloidal or viscous substances.
[0003] Mussel mucin is widely used in the medical field. Mussel mucin has broad application prospects in surgery, tissue repair and bio-artificial materials. At the same time, mussel mucin can also be used to prepare hydrogels, in-situ glues, drug controlled release systems, etc.
[0004] However, the existing mussel mucin has a certain adhesion ability during use, but its adhesion effect may not be ideal on certain material surfaces or under specific environments, because the existing mussel mucin is rich in DOPA, which is a special amino acid obtained by hydroxylation modification of tyrosine, and its content can reach 20-30mol%, which contributes significantly to the adhesion ability. However, when the catechol structure in DOPA is oxidized to quinone, it will be difficult to form hydrogen bonds between DOPA and the material surface, resulting in a significant weakening or disappearance of the adhesion energy of the protein. At the same time, the output of the existing mussel mucin is limited by multiple factors such as cell growth rate and nutrient supply, resulting in low output, and in the prior art, the purification process of mussel mucin may be complicated and inefficient, and it is difficult to maintain its biological activity during the purification process.
[0005] Therefore, there is an urgent need for a preparation method of mussel mucin based on genetic engineering to solve the technical problems existing in the above-mentioned prior art. Summary of the invention
[0006] The invention overcomes the shortcomings of the prior art and provides a method for preparing mussel mucin based on genetic engineering modification.
[0007] To achieve the above object, the technical solution adopted by the present invention is: a method for preparing mussel mucin based on genetic engineering, comprising the following steps:
[0008] S1. Select the mussel mucin gene, perform artificial synthesis or PCR amplification according to the gene sequences of mussel mucin and dopa group modification enzyme, clone the mussel mucin and dopa group modification enzyme into expression vectors respectively, construct recombinant plasmids, and then transform the recombinant plasmids into Escherichia coli competent cells, obtain positive clones through antibiotic screening, and perform plasmid verification and sequencing confirmation to obtain mussel mucin capable of expressing dopa group modification;
[0009] S2, placing the mussel mucin obtained in step S1) into a fermentation tank, subjecting the mussel mucin to bacterial fermentation under optimized culture conditions, and optimizing the ratio of nutrients in the mussel mucin through single factor experiments or orthogonal experiments during the fermentation process, culturing genetically engineered bacteria, and obtaining improved mussel mucin;
[0010] S3. According to the bacterial characteristics of the improved mussel mucin, centrifugation or ultrafiltration is used to separate and break the cells, and then affinity chromatography, ion exchange chromatography and gel filtration chromatography are combined, and N-hydroxysuccinimide ester and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide chemical modifiers are introduced to activate and couple the dopa group to extract the mussel mucin with bacterial expression in the improved mussel mucin;
[0011] S4. Under low temperature and vacuum conditions, the mussel mucin extracted in step S3) is concentrated and freeze-dried, and after grinding and crushing, powdered mussel mucin is obtained.
[0012] In a preferred embodiment of the present invention, in step S1), the gene of mussel mucin and the expression vector are digested with a restriction endonuclease to produce matching sticky ends or blunt ends, and the gene of mussel mucin and the expression vector are connected by DNA ligase to form the recombinant plasmid.
[0013] In a preferred embodiment of the present invention, in step S1), before constructing the recombinant plasmid, at least one of glycosyltransferase, hydroxylase or cross-linking enzyme is added to the mussel mucin, and the antibiotic is one or more of ampicillin, kanamycin, chloramphenicol, tetracycline or spectinomycin.
[0014] In a preferred embodiment of the present invention, in step S2), the optimized culture conditions include: an initial temperature of 25 to 45°C; after maintaining the initial temperature for 2 to 4 hours, adjusting the temperature after induction to 28 to 35°C; a stirring speed of 150 to 300 rpm; a dissolved oxygen concentration in the fermentation tank of not less than 30%; and after continuous fermentation for 5 to 8 hours, adding isopropyl-β-D-thiogalactoside at a concentration of 0.08 to 0.15 mM to the fermentation tank.
[0015] In a preferred embodiment of the present invention, in step S3), the activation and coupling reaction process includes: mixing N-hydroxysuccinimide ester and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide in a mass ratio of 1:1 to form an activator, and placing the activator in a solution containing improved mussel mucin to activate the dopa group and undergo coupling reaction with other molecules.
[0016] In a preferred embodiment of the present invention, in step S4), the mussel mucin extracted in step S3) is pre-frozen, the pre-freezing temperature is -70 to -85°C, and the pre-freezing time is 1.5 to 3 hours; the freeze-drying time is 20 to 48 hours, and the freezing temperature is -70 to -90°C.
[0017] In a preferred embodiment of the present invention, in step S4), the vacuum conditions include: vacuum drying temperature is -45 to 55°C; and the vacuum degree is less than 0.01 mBar.
[0018] In a preferred embodiment of the present invention, in step S3), the cell disruption is one of mechanical disruption, chemical disruption or physical disruption, the mechanical disruption includes: an ultrasonic disruptor or a homogenizer; the chemical disruption includes: lysozyme or SDS; the physical disruption is a high-pressure homogenizer.
[0019] In a preferred embodiment of the present invention, in step S3), the affinity chromatography uses affinity to separate the improved mussel mucin from the mussel mucin obtained in step S1); the ion exchange chromatography is used to remove other protein components in the improved mussel mucin; and the gel filtration chromatography separates all protein molecules according to their sizes.
[0020] In a preferred embodiment of the present invention, the affinity chromatography is a column containing nickel ions, the ion exchange chromatography is DEAE-cellulose or CM-cellulose, and the gel filtration chromatography is Sephadex G-75 or Superdex 200.
[0021] The present invention solves the defects existing in the background technology and has the following beneficial effects:
[0022] (1) The present invention introduces a DOPA group-modifying enzyme through genetic engineering. DOPA is a unique amino acid whose side chain is mainly catechol. This active group has affinity diversity and chemical versatility, which enables DOPA to form a variety of chemical bonds, including hydrogen bonds, metal coordination bonds, and covalent bonds, thereby enhancing the adhesion effect and enhancing the adhesion ability of mussel mucin, making its adhesion on the surface of various materials more firm and durable.
[0023] (2) During the fermentation process, the present invention optimizes the ratio of nutrients and the ratio of nutrients in the culture medium, such as carbon source, nitrogen source, inorganic salt, growth factor, etc., so as to provide various nutrients required for cell growth, promote rapid growth and division of cells, and thus increase the yield of mussel mucin.
[0024] (3) The present invention separates and disrupts cells by centrifugation or ultrafiltration, combines multiple chromatography techniques and the introduction of chemical modifiers, thereby providing an efficient and reliable method for purifying mussel mucin. This method can significantly improve the purity and activity of mussel mucin, making it have a better effect in application. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art are briefly introduced below. Obviously, the drawings described below are only some embodiments recorded in the present invention. For those of ordinary skill in the art, other drawings can be obtained based on these drawings without creative work.
[0026] Figure 1 It is a process flow chart of the invention of fermenting mussel mucin with genetically engineered bacteria;
[0027] Figure 2 is a flow chart of extraction and purification of mussel mucin of the present invention;
[0028] Figure 3 It is the changes of cell density, mussel mucin production and dissolved oxygen concentration during the fermentation process of the present invention. DETAILED DESCRIPTION
[0029] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0030] In the following description, many specific details are set forth to facilitate a full understanding of the present invention, but the present invention may also be implemented in other ways different from those described herein. Therefore, the protection scope of the present invention is not limited to the specific embodiments disclosed below.
[0031] In the description of the present application, it should be understood that the terms "center", "longitudinal", "lateral", "up", "down", "front", "back", "left", "right", "vertical", "horizontal", "top", "bottom", "inside", "outside", etc., indicating the orientation or positional relationship, are based on the orientation or positional relationship shown in the drawings, and are only for the convenience of describing the present application and simplifying the description, rather than indicating or implying that the device or element referred to must have a specific orientation, be constructed and operated in a specific orientation, and therefore cannot be understood as limiting the scope of protection of the present application. In addition, the terms "first", "second", etc. are only used for descriptive purposes, and cannot be understood as indicating or implying relative importance or implicitly indicating the number of technical features indicated. Therefore, features defined as "first", "second", etc. may explicitly or implicitly include one or more of the features. In the description of the invention, unless otherwise specified, "multiple" means two or more.
[0032] In the description of this application, it should be noted that, unless otherwise clearly specified and limited, the terms "installed", "connected", and "connected" should be understood in a broad sense, for example, it can be a fixed connection, a detachable connection, or an integral connection; it can be a mechanical connection or an electrical connection; it can be directly connected or indirectly connected through an intermediate medium, and it can be the internal communication of two components. For ordinary technicians in this field, the specific meanings of the above terms in this application can be understood by specific circumstances.
[0033] like Figure 1 As shown, a method for preparing mussel mucin based on genetic engineering modification comprises the following steps:
[0034] S1. Select the mussel mucin gene, perform artificial synthesis or PCR amplification according to the gene sequences of mussel mucin and dopa group modification enzyme, clone the mussel mucin and dopa group modification enzyme into expression vectors respectively, construct recombinant plasmids, and then transform the recombinant plasmids into Escherichia coli competent cells, obtain positive clones through antibiotic screening, and perform plasmid verification and sequencing confirmation to obtain mussel mucin capable of expressing dopa group modification; transform the recombinant plasmid into Escherichia coli competent cells, and obtain positive clones through antibiotic screening, thereby ensuring that only bacteria with successfully introduced recombinant plasmids can grow, thereby simplifying the subsequent purification steps.
[0035] The genes of mussel mucin and dopa-modified enzyme were obtained by artificial synthesis or PCR amplification, and cloned into expression vectors to construct recombinant plasmids capable of expressing dopa-modified mussel mucin, which provided a basis for subsequent bacterial fermentation expression.
[0036] In step S1), the mussel mucin gene and the expression vector are digested with restriction endonucleases to generate matching sticky ends or blunt ends, and the mussel mucin gene and the expression vector are connected with DNA ligase to form a recombinant plasmid.
[0037] In step S1), before constructing the recombinant plasmid, at least one of glycosyltransferase, hydroxylase or cross-linking enzyme is added to the mussel mucin, and the antibiotic is one or more of ampicillin, kanamycin, chloramphenicol, tetracycline or spectinomycin.
[0038] like Figure 2 As shown, S2, the mussel mucin obtained in step S1) is placed in a fermentation tank, and the mussel mucin is subjected to bacterial fermentation under optimized culture conditions, and during the fermentation process, the ratio of nutrients in the mussel mucin is optimized through single factor experiments or orthogonal experiments, and genetically engineered bacteria are cultivated to obtain improved mussel mucin;
[0039] In step S2), the optimized culture conditions include: the initial temperature is 25-45°C; after maintaining the initial temperature for 2-4 hours, the temperature after induction is adjusted to 28-35°C; the stirring speed is 150-300rpm; the dissolved oxygen concentration in the fermentation tank is not less than 30%; after continuous fermentation for 5-8 hours, isopropyl-β-D-thiogalactoside with a concentration of 0.08-0.15mM is added to the fermentation tank. Isopropyl-β-D-thiogalactoside is added as an inducer during the fermentation process to promote the expression of mussel mucin.
[0040] S3. According to the bacterial characteristics of the improved mussel mucin, centrifugation or ultrafiltration is used to separate and break the cells, and then affinity chromatography, ion exchange chromatography and gel filtration chromatography are combined, and N-hydroxysuccinimide ester and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide chemical modifiers are introduced to activate and couple the dopa group to extract the mussel mucin with bacterial expression in the improved mussel mucin;
[0041] In a preferred embodiment, N-hydroxysuccinimide ester (NHS) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) are used to activate and couple the dopa group. A nickel ion affinity chromatography column is used in the affinity chromatography step to ensure the acquisition of high-purity mussel mucin with a purity of more than 98%. A variety of chromatographic techniques such as affinity chromatography, ion exchange chromatography and gel filtration chromatography are combined to extract mussel mucin with high purity.
[0042] In step S3), the process of activation and coupling reaction includes: mixing N-hydroxysuccinimide ester and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide in a mass ratio of 1:1 to form an activator, and placing the activator in a solution containing improved mussel mucin to activate the dopa group and undergo coupling reaction with other molecules. Chemical modifiers such as N-hydroxysuccinimide ester and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide are introduced to activate and couple the dopa group. This step enhances the functionality and stability of mussel mucin.
[0043] In step S3), the cells are broken by mechanical, chemical or physical means. Mechanical breaking includes ultrasonic breaking or homogenizer; chemical breaking includes lysozyme or SDS; and physical breaking includes high pressure homogenizer.
[0044] In step S3), affinity chromatography uses affinity to separate the improved mussel mucin from the mussel mucin obtained in step S1); ion exchange chromatography is used to remove other protein components in the improved mussel mucin; and gel filtration chromatography separates all protein molecules according to their sizes.
[0045] Affinity chromatography uses a column containing nickel ions, ion exchange chromatography uses DEAE-cellulose or CM-cellulose, and gel filtration chromatography uses Sephadex G-75 or Superdex 200.
[0046] S4. Under low temperature and vacuum conditions, the mussel mucin extracted in step S3) is concentrated and freeze-dried, and after grinding and crushing, powdered mussel mucin is obtained.
[0047] In a preferred embodiment, the fermentation conditions include controlling temperature, pH value and dissolved oxygen concentration to maximize the yield and quality of mussel mucin. The optimal fermentation conditions are 37°C, pH 6.5, dissolved oxygen concentration maintained above 30%, fermentation for 48 hours, and the final protein yield reaches 250 mg / L.
[0048] The chemical modification step involves the introduction of specific functional groups onto the dopa moiety to improve adhesion properties and bioactivity.
[0049] In step S4), the mussel mucin extracted in step S3) is pre-frozen at a temperature of -70 to -85°C for 1.5 to 3 hours; the freeze-drying time is 20 to 48 hours, and the freezing temperature is -70 to -90°C.
[0050] In step S4), the vacuum conditions include: vacuum drying temperature of -45 to 55°C; vacuum degree of less than 0.01 mBar.
[0051] The chemically modified dopa group forms a quinone structure through enzymatic oxidation, thereby enhancing adhesion performance and stability. In in vitro experiments, the adhesion strength of the modified mussel mucin increased by about 70%. Mussel mucin showed excellent biocompatibility and low immunogenicity in both in vitro and in vivo experiments.
[0052] The product can be used in various medical scenarios, such as surgical wound closure, tissue engineering scaffold fixation and drug controlled release system. In in vitro and in vivo experiments, the fusion protein showed excellent effects in wound healing and tissue repair, shortening the healing time by about 40%. The product showed excellent antibacterial properties and the ability to promote tissue regeneration in in vitro and in vivo experiments.
[0053] In order to facilitate the understanding of the professional terms used in the technical solution of the present invention, it is necessary to further explain here:
[0054] Genetic engineering: A biotechnology technique that involves the direct manipulation of an organism's genes to alter its genetic characteristics. This usually involves the introduction of foreign genes into an organism (such as bacteria) to cause it to express a new protein.
[0055] PCR amplification: The abbreviation of polymerase chain reaction (PCR), is a molecular biology technique used to amplify specific DNA fragments in vitro.
[0056] Expression vector: A DNA molecule used to introduce foreign genes into host cells and express them. Expression vectors usually contain necessary genetic elements such as promoters, terminators and selection markers.
[0057] Glycosyltransferase: Glycosyltransferase can catalyze the transfer of sugar groups from donor molecules to acceptor molecules (such as proteins) to form glycosidic bonds. In the modification of mussel mucin, glycosylation can increase the stability and biological activity of proteins. Through the modification of glycosyltransferase, the solubility, adhesion and immunogenicity of mussel mucin can be improved.
[0058] Hydroxylase: Hydroxylase catalyzes the hydroxylation of specific amino acids in proteins, such as hydroxylation of tyrosine to DOPA. In the preparation of mussel mucin, although DOPA is usually obtained by tyrosinase-modified DOPA, hydroxylases may be used for hydroxylation of other amino acids to further increase the functionality of mucin.
[0059] Cross-linking enzyme: Cross-linking enzyme can catalyze the cross-linking reaction between protein molecules to form a stable protein network. In the application of mussel mucin, the cross-linking reaction can enhance the adhesion strength and durability of mucin.
[0060] Application: Through the modification of cross-linking enzymes, mussel mucin can form a more solid and lasting attachment on the surface of various materials
[0061] Recombinant plasmid: A hybrid DNA molecule formed by inserting a foreign DNA fragment into a vector DNA.
[0062] E. coli competent cells: A specially modified bacterial cell that is able to receive and express foreign DNA.
[0063] Antibiotic selection: A method used to select bacterial cells into which foreign DNA has been successfully introduced. Only cells containing a gene for resistance to a specific antibiotic will be able to grow on a medium containing that antibiotic.
[0064] Plasmid verification and sequencing confirmation: Laboratory techniques are used to verify that the plasmid contains the correct foreign gene, and DNA sequencing is performed to confirm its sequence.
[0065] Restriction endonuclease: An enzyme that recognizes and cuts specific DNA sequences and is used to construct recombinant DNA molecules.
[0066] DNA ligase: An enzyme that can join two DNA fragments and is used to construct recombinant plasmids.
[0067] Fermenter: A container used for microbial fermentation, in which suitable growth conditions and nutrients are provided to promote the growth of microorganisms and the production of products.
[0068] Optimize culture conditions: Maximize product yield and quality by adjusting various parameters during the fermentation process (such as temperature, pH value, dissolved oxygen concentration, etc.).
[0069] Isopropyl-β-D-thiogalactoside (IPTG): A commonly used inducer to promote the expression of specific genes in bacteria.
[0070] Centrifugation and ultrafiltration: Techniques used to separate and purify biomolecules. Centrifugation separates molecules of different weights through the force of rotation; ultrafiltration uses a semipermeable membrane to separate molecules based on size.
[0071] Affinity chromatography: A separation technique that exploits the specific interactions between biomolecules. For example, a column containing nickel ions can specifically adsorb proteins containing a histidine tag.
[0072] Ion exchange chromatography: A technique that separates molecules based on their charge. DEAE-cellulose and CM-cellulose are commonly used ion exchangers.
[0073] Gel filtration chromatography: A technique for separation based on molecular size. Sephadex G-75 and Superdex 200 are commonly used gel filtration media.
[0074] Concentration and lyophilization: Techniques used to separate biomolecules from solution and dry them into powder form. Concentration increases the concentration of biomolecules by removing water from the solution; lyophilization removes water by freezing and vacuum drying.
[0075] Prefreezing: The step of freezing the sample before lyophilization helps to preserve the structure and activity of the sample.
[0076] Vacuum conditions: A low-pressure environment used during the freeze-drying process to help remove water from the sample and prevent it from oxidizing or degrading.
[0077] Enzymatic oxidation: The process of promoting oxidation reactions through the action of enzymes can change the structure and function of biological molecules.
[0078] Quinone structure: A ring structure containing two double bonds that can be formed by oxidation reactions and has an important influence on adhesion properties and stability.
[0079] Biocompatibility and low immunogenicity: Biocompatibility refers to the ability of a material to interact with an organism without causing adverse reactions; low immunogenicity refers to the property of a material that is not likely to cause an immune response.
[0080] Medical scenarios: refers to application scenarios in the medical field, such as surgery, tissue engineering, drug controlled release systems, etc.
[0081] Antibacterial properties and tissue regeneration: Antibacterial properties refer to the ability of materials to inhibit or kill bacteria; tissue regeneration refers to the ability of materials to promote the growth and repair of biological tissues.
[0082] Embodiment 1
[0083] The recombinant mussel mucin sequence of the present invention, wherein the collagen peptide truncated sequence is derived from the known human type III collagen sequence, and the mussel mucin Mfp-5 truncated peptide sequence is derived from mussel mucin (GenBank: ABE01084.1). A basic repeating unit fragment (about 60 amino acids) of human type III collagen is selected, and the collagen peptide basic repeating unit fragment is connected to the head and tail of the Mfp-5 protein respectively to form a fusion peptide of the collagen and Mfp-5 protein, and linkers are added at the connection points to form a recombinant mussel mucin sequence. A 6×His tag and a terminator are added to the C-terminus, and the DNA sequence encoding the fusion protein is optimized and designed according to the preference of the host cell Escherichia coli, so that the fusion protein is more suitable for expression in the selected host.
[0084] The optimized recombinant mussel mucin gene sequence is synthesized into gene fragments, and the mussel mucin gene and the expression vector are digested with restriction endonucleases to generate matching sticky ends, and the mussel mucin gene and the expression vector are connected with DNA ligase to form the recombinant plasmid.
[0085] The constructed recombinant plasmid was linearized and introduced into competent cells of the host cell Escherichia coli BL21 by chemical transformation.
[0086] Positive clones were obtained by screening with the antibiotic ampicillin, and plasmid verification and sequencing were performed to confirm the results. Plasmid construction: The optimized recombinant mussel mucin gene sequence was inserted into the pET-28a expression vector through the EcoRI and NotI restriction sites to construct a recombinant plasmid. Plasmid linearization: The constructed recombinant plasmid was linearized using the QuickCutSacI enzyme. Transformation: The linearized recombinant plasmid was introduced into the competent cells of Escherichia coli BL21 by electroporation. Screening and verification: Screening was performed on LB medium containing ampicillin to obtain positive clones, and plasmid verification and sequencing were performed to confirm the results.
[0087] The host cells containing the recombinant plasmid are cultured under optimized culture conditions, and the inducer IPTG is added to induce expression. After induced expression, the bacteria are collected by centrifugation or ultrafiltration, and the cells are broken using an ultrasonic disruptor to release the recombinant protein. Pick a single colony and inoculate it in BMGY medium, and collect the bacteria after culturing to a certain OD value. Resuspend the bacteria in BMMY medium and induce expression. Methanol is added to the culture medium every 24 hours, and bacterial samples are taken at different time points after induction, and the expression supernatant is collected by centrifugation. The expression of the target protein is analyzed by SDS-PAGE electrophoresis.
[0088] The recombinant protein was purified by affinity chromatography using a nickel ion column, DEAE-cellulose ion exchange chromatography, and Sephadex G-75 gel filtration chromatography to remove other impurities and protein components. During the purification process, chemical modifiers N-hydroxysuccinimide ester and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide were introduced to activate and couple the dopa group to enhance the function and stability of the recombinant protein.
[0089] The purified recombinant mussel mucin was concentrated and pre-frozen before freeze-drying at a temperature of -75°C for 2 hours to further protect its structure and activity. The product was then freeze-dried at a vacuum drying temperature of -50°C, a vacuum degree of less than 0.01 mBar, a freeze-drying time of 24 hours, and a freezing temperature of -80°. The freeze-dried recombinant protein was ground and crushed to obtain a powdered recombinant mussel mucin product.
[0090] Culture conditions: E. coli BL21 containing the recombinant plasmid was cultured at 37°C for 12-16 hours. Induced expression: In the fermenter, the initial temperature was set at 37°C for 3 hours and then decreased to 30°C. IPTG was added after 6 hours of fermentation to a final concentration of 0.1 mM and fermentation was continued for 48 hours.
[0091] Extraction: Collect the cells by centrifugation (30 minutes, 4°C), and then use an ultrasonic disruptor to disrupt the cells for 20 minutes in an ice bath (30 seconds for each ultrasound, 30 seconds interval). Purification: Ultrafiltration (1-2 hours, 4°C, using a 10-30 kDa cut-off membrane), affinity chromatography (4-6 hours, columns containing nickel ions), ion exchange chromatography (4-6 hours, DEAE-cellulose or CM-cellulose) and gel filtration chromatography (4-6 hours, Sephadex G-75 or Superdex 200) were performed in sequence.
[0092] Concentration: The purified recombinant mussel mucin is concentrated. Freeze-drying: Freeze at -80°C for 2 hours, then freeze-dry at -50°C and vacuum degree <0.01mBar for about 24 hours. Grinding: Grind the freeze-dried recombinant protein to obtain a powdered recombinant mussel mucin product.
[0093] Experiment on the beneficial effects of recombinant mussel mucin:
[0094] Experimental purpose: To verify the adhesion strength and healing effect of genetically engineered mussel mucin in vitro and in vivo.
[0095] Experimental groups: Experimental group: using genetically engineered mussel mucin. Control group: using unmodified natural mussel mucin or similar products on the market.
[0096] Experimental materials: Genetically engineered mussel mucin samples; natural mussel mucin or commercially available control samples
[0097] Experimental animals: mice; cell culture plates and culture medium; adhesion strength testing equipment; histological staining reagents and microscopes; scalpels and suture materials.
[0098] Experimental process: In vitro adhesion strength test, the average adhesion strength of the experimental group was 70N / cm 2 ; Average adhesion strength of the control group: 40N / cm 2 ; The percentage increase in adhesion strength is 75%.
[0099] Sample preparation: The mussel mucin samples of the experimental and control groups were processed according to standard procedures to ensure consistent concentrations.
[0100] Cell Culture: Grow appropriate cell lines in cell culture plates until cells reach appropriate density.
[0101] Adhesion experiment: The processed mussel mucin sample was evenly spread on the surface of the cell culture plate, and then the cells were inoculated thereon and cultured for a certain period of time.
[0102] Adhesion strength test: Use a universal material testing machine to perform a tensile test on the cell layer and record the adhesion strength data.
[0103] In vivo healing effect evaluation: Animal selection: Twelve mice of similar size were selected and divided into an experimental group and a control group, with 6 mice in each group. Standard surgical operations were performed to create consistent wounds.
[0104] Sample application: Apply the mussel mucin samples of the experimental and control groups to the wounds, ensuring even coverage.
[0105] Postoperative care: Postoperative care was performed according to standard procedures and wound healing was recorded.
[0106] Histological evaluation: At the predetermined time points: 3rd, 7th, and 14th days after surgery, wound tissues were obtained for histological staining to observe wound healing.
[0107] Data analysis: The wound healing time, healing quality and other indicators were statistically analyzed and compared among the groups.
[0108] In vivo healing effect assessment:
[0109] Animal species and number: Determined according to the experimental ethics approval, at least 6 animals per group.
[0110] Wound model: To ensure consistency and reproducibility, a full-thickness skin incision was selected.
[0111] Postoperative observation time point: determined according to the wound healing cycle, selected as 3 days, 7 days, and 14 days after surgery.
[0112] Histological staining method: HE staining was selected to evaluate wound healing.
[0113] The average healing time in the experimental group was 6 days, and the average healing time in the control group was 10 days; the percentage of shortening the healing time was 40%.
[0114] In in vitro experiments, the improvement of adhesion strength is a key indicator, which is directly related to the effectiveness of mussel mucin in practical applications. Experimental data show that the adhesion strength of mussel mucin produced by this method increased by about 75%, which is not only close to the expected target value of 70%, but also exceeded this value, indicating that this method has a significant effect in improving adhesion strength. This improvement is attributed to the dopa group modification introduced by genetic engineering, which enhances the interaction between mussel mucin and the substrate, thereby improving adhesion strength.
[0115] In the in vivo experiment, the shortening of healing time is another important evaluation index. The experimental data showed that the healing time was shortened by 40% after the mussel mucin produced by this method was used. This result not only verifies the effectiveness of this method in in vivo applications, but also shows that it has the potential to promote wound healing. The shortening of healing time is attributed to the optimization of the mussel mucin structure brought about by genetic engineering, which makes it more stable and more biologically active in the in vivo environment, thereby accelerating the wound healing process.
[0116] When the present invention is used, genetic engineering modification: restriction endonucleases are used to enzymatically cut the gene of mussel mucin and the expression vector to produce matching sticky ends or flat ends, and the gene of the mussel mucin and the expression vector are connected by DNA ligase to form the recombinant plasmid. Optimize fermentation conditions: fermentation is carried out using optimized culture conditions, including controlling the initial temperature, adjusting the temperature after induction, stirring speed, dissolved oxygen concentration and fermentation time, etc., to improve fermentation efficiency and yield. Accurately control activation and coupling reactions: N-hydroxysuccinimide ester and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide are mixed in a mass ratio of 1:1 to form an activator, and the activator is placed in a solution containing improved mussel mucin to activate the dopa group and undergo coupling reactions with other molecules to improve product purity and yield. Improved extraction and purification methods: Use centrifugation or ultrafiltration to separate and disrupt cells, then combine affinity chromatography, ion exchange chromatography and gel filtration chromatography, and introduce chemical modifiers to activate and couple the dopa group to extract the bacterially expressed mussel mucin in the improved mussel mucin to improve the purity and quality of the final product. Concentration and freeze-drying: Under low temperature and vacuum conditions, the extracted mussel mucin is concentrated and freeze-dried, and after grinding and crushing, a powdered mussel mucin is obtained to improve the storage stability of the product.
[0117] The improved mussel mucin provided by the present invention has excellent adhesion properties and biocompatibility, and can be widely used in the fields of medicine, bioengineering, and materials science. For example, in the medical field, the improved mussel mucin can be used to manufacture artificial organs, tissue engineering, and drug delivery systems; in the field of bioengineering, the improved mussel mucin can be used to manufacture biosensors, bioreactors, and bioseparation materials; in the field of materials science, the improved mussel mucin can be used to manufacture high-strength, corrosion-resistant, and biocompatible materials. Secondly, the method for preparing the improved mussel mucin provided by the present invention is simple to operate, easy to control, and suitable for large-scale production, which provides the possibility for its practical application. Finally, the extraction and purification method provided by the present invention can effectively remove impurities and improve the purity and quality of the product, which provides a guarantee for its practical application.
[0118] The above is based on the ideal embodiment of the present invention. Through the above description, relevant personnel can make various changes and modifications without departing from the technical concept of the present invention. The technical scope of the present invention is not limited to the content in the specification, and the technical scope must be determined according to the scope of the claims.
Claims
1. A method for preparing mussel mucin based on genetic engineering, characterized in that: The following steps are involved: S1. Select the mussel mucin gene, perform artificial synthesis or PCR amplification according to the gene sequences of mussel mucin and dopa group modification enzyme, clone the mussel mucin and dopa group modification enzyme into expression vectors respectively, construct recombinant plasmids, and then transform the recombinant plasmids into Escherichia coli competent cells, obtain positive clones through antibiotic screening, and perform plasmid verification and sequencing confirmation to obtain mussel mucin capable of expressing dopa group modification; S2, placing the mussel mucin obtained in step S1) into a fermentation tank, subjecting the mussel mucin to bacterial fermentation under optimized culture conditions, and optimizing the ratio of nutrients in the mussel mucin through single factor experiments or orthogonal experiments during the fermentation process, culturing genetically engineered bacteria, and obtaining improved mussel mucin; S3. According to the bacterial characteristics of the improved mussel mucin, centrifugation or ultrafiltration is used to separate and break the cells, and then affinity chromatography, ion exchange chromatography and gel filtration chromatography are combined, and N-hydroxysuccinimide ester and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide chemical modifiers are introduced to activate and couple the dopa group to extract the mussel mucin with bacterial expression in the improved mussel mucin; S4. Under low temperature and vacuum conditions, the mussel mucin extracted in step S3) is concentrated and freeze-dried, and after grinding and crushing, powdered mussel mucin is obtained.
2. The method for preparing a genetically engineered mussel mucin according to claim 1, characterized in that: In step S1), the mussel mucin gene and the expression vector are digested with restriction endonucleases to generate matching sticky ends or blunt ends, and the mussel mucin gene and the expression vector are connected with DNA ligase to construct the recombinant plasmid.
3. The method for preparing a genetically engineered mussel mucin according to claim 1, characterized in that: In step S1), before constructing the recombinant plasmid, at least one of glycosyltransferase, hydroxylase or cross-linking enzyme is added to the mussel mucin, and the antibiotic is one or more of ampicillin, kanamycin, chloramphenicol, tetracycline or spectinomycin.
4. The method for preparing a genetically engineered mussel mucin according to claim 1, characterized in that: In step S2), the optimized culture conditions include: an initial temperature of 25 to 45°C; after maintaining the initial temperature for 2 to 4 hours, adjusting the temperature after induction to 28 to 35°C; a stirring speed of 150 to 300 rpm; a dissolved oxygen concentration in the fermenter of not less than 30%; and after continuous fermentation for 5 to 8 hours, adding isopropyl-β-D-thiogalactoside at a concentration of 0.08 to 0.15 mM to the fermenter.
5. The method for preparing a genetically engineered mussel mucin according to claim 1, characterized in that: In step S3), the activation and coupling reaction process includes: mixing N-hydroxysuccinimide ester and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide in a mass ratio of 1:1 to form an activator, and placing the activator in a solution containing improved mussel mucin to activate the dopa group and undergo coupling reaction with other molecules.
6. The method for preparing mussel mucin based on genetic engineering according to claim 1, characterized in that: In step S4), the mussel mucin extracted in step S3) is pre-frozen at a temperature of -70 to -85°C for 1.5 to 3 hours; the freeze-drying time is 20 to 48 hours, and the freezing temperature is -70 to -90°C.
7. The method for preparing mussel mucin based on genetic engineering according to claim 1, characterized in that: In step S4), the vacuum conditions include: vacuum drying temperature is -45 to 55°C; vacuum degree is less than 0.01 mBar.
8. The method for preparing mussel mucin based on genetic engineering according to claim 1, characterized in that: In step S3), the cell disruption is one of mechanical disruption, chemical disruption or physical disruption. The mechanical disruption includes: an ultrasonic disruptor or a homogenizer; the chemical disruption includes: lysozyme or SDS; the physical disruption is a high-pressure homogenizer.
9. The method for preparing a genetically engineered mussel mucin according to claim 1, characterized in that: In step S3), the affinity chromatography uses affinity to separate the improved mussel mucin from the mussel mucin obtained in step S1); the ion exchange chromatography is used to remove other protein components in the improved mussel mucin; and the gel filtration chromatography separates all protein molecules according to their sizes.
10. The method for preparing mussel mucin based on genetic engineering according to claim 9, characterized in that: The affinity chromatography is a column containing nickel ions, the ion exchange chromatography is DEAE-cellulose or CM-cellulose, and the gel filtration chromatography is Sephadex G-75 or Superdex 200.
Citation Information
Cited By
Recombinant mussel mucin structure modification method
CN120699121A
Preparation method of recombinant mussel mucoprotein
CN120843564A
Improved method for the production of mussel adhesive protein by engineered yeast fermentation
GB2704650A
